LGS
74 programs · 69 companies
Programs
74
Companies
69
Trials
72
MOAs
45
WEE1iTYK2iIL-13iWRNiCAR-T BCMATNFiCD47iPI3KiRAS(ON)iSHP2i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-853 | Phase 1 | PRMT5 | ||
| MRK-2473 | Phase 1/2 | Nectin-4 | ||
| Gozesotorasib | NDA/BLA | HER2 | ||
| BMY-7975 | Phase 1 | MALT1 | ||
| NVO-9087 | Phase 1/2 | Tau | ||
| Ribozanubrutinib | Approved | GPRC5D | ||
| Zanurapivir | NDA/BLA | EGFR | ||
| SRP-3270 | Phase 1/2 | SGLT2 | ||
| 180-3597 | Preclinical | SHP2 | ||
| 369-4107 | Phase 2 | TNFα | ||
| Elrainavolisib | Preclinical | Nectin-4 | ||
| Suracapivasertib | Preclinical | PRMT5 | ||
| Ivotuximab | Phase 2 | CD123 | ||
| Semainavolisib | Phase 2 | B7-H3 | ||
| Surarasimod | Phase 2 | SHP2 | ||
| RCU-6379 | Phase 1/2 | DLL3 | ||
| AGI-4446 | Phase 3 | PSMA | ||
| Fixamavacamten | Phase 2 | SOS1 | ||
| BVN-7642 | Phase 2 | CFTR | ||
| Polalucimab | Phase 1/2 | KRASG12C | ||
| IPN-3758 | Phase 1 | B7-H3 | ||
| Zoribrutinib | Preclinical | B7-H3 | ||
| Rilulucimab | Phase 2 | PSMA | ||
| Voxarapivir | Phase 2 | GPRC5D | ||
| GUS-IIT-951 | Approved | USP1 | ||
| INS-408 | Phase 1 | WRN | ||
| AVB-7847 | Phase 1/2 | C5 | ||
| INO-2656 | Approved | WEE1 | ||
| Mavunesiran | Preclinical | JAK1 | ||
| Adagrazumab | Phase 3 | CGRP | ||
| Bemarelsin | Phase 2/3 | CGRP | ||
| GOS-9676 | Phase 1/2 | PD-L1 | ||
| Datolucimab | Phase 1/2 | Tau | ||
| Pemibrutinib | Approved | TIM-3 | ||
| EYE-3796 | Phase 3 | CFTR | ||
| CLO-5164 | Phase 1 | Nectin-4 | ||
| Lisoderotide | Phase 3 | SHP2 | ||
| IMM-2816 | Approved | Cl18.2 | ||
| IMM-5415 | Preclinical | PD-1 | ||
| G1-2036 | Phase 3 | Tau | ||
| KMD-8521 | Preclinical | BCL-2 | ||
| CAN-4040 | Phase 1/2 | CD47 | ||
| 601-7487 | Phase 2 | Menin | ||
| Pexasacituzumab | Preclinical | USP1 | ||
| Nidacilimab | Preclinical | JAK1 | ||
| Polafotisoran | Phase 2/3 | PLK4 | ||
| Elracapivasertib | Preclinical | MET | ||
| 302-9165 | Approved | PSMA | ||
| Zoritapinarof | Phase 1 | SOS1 | ||
| LMN-8636 | Phase 3 | BET | ||
| BBI-9525 | NDA/BLA | PLK4 | ||
| Lisocilimab | Phase 2/3 | FXIa | ||
| Terazanubrutinib | Preclinical | SMN2 | ||
| Zorizasiran | Phase 1 | CD19 | ||
| Gozederotide | NDA/BLA | WEE1 | ||
| Gozenesiran | NDA/BLA | PARP | ||
| Talazumab | Phase 2/3 | B7-H3 | ||
| ALM-7482 | Approved | C5 | ||
| REC-373 | Phase 1 | SGLT2 | ||
| NYK-4396 | Preclinical | PD-L1 | ||
| Doxazumab | Phase 1/2 | FGFR | ||
| CNT-5081 | Phase 3 | BET | ||
| Pemimavacamten | Phase 1 | PI3Kα | ||
| Tezebrutinib | Preclinical | HER2 | ||
| Rimabrutinib | Approved | WRN | ||
| ALK-3993 | Phase 3 | SOS1 | ||
| SIA-2247 | Preclinical | FLT3 | ||
| Polabrutinib | Preclinical | FcRn | ||
| Adagranesiran | Phase 2 | USP1 | ||
| INS-IIT-597 | Phase 2/3 | VEGF | ||
| PET-IIT-181 | Approved | PARP | ||
| SEV-IIT-475 | Approved | AuroraA | ||
| Tixasotorasib | Preclinical | PSMA | ||
| ADA-4330 | Approved | Menin |
Trials (72)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03751098 | NVO-9087 | Phase 1/2 | Terminated |
| NCT06600219 | Ribozanubrutinib | Approved | Active |
| NCT05185046 | Ribozanubrutinib | Approved | Active |
| NCT03235206 | Zanurapivir | NDA/BLA | Not yet recr... |
| NCT06882797 | SRP-3270 | Phase 1/2 | Terminated |
| NCT08740177 | SRP-3270 | Phase 1/2 | Recruiting |
| NCT04779591 | 180-3597 | Preclinical | Recruiting |
| NCT04032419 | 369-4107 | Phase 2 | Active |
| NCT07000897 | Elrainavolisib | Preclinical | Terminated |
| NCT08960274 | Suracapivasertib | Preclinical | Terminated |
| NCT06585697 | Ivotuximab | Phase 2 | Terminated |
| NCT04408639 | Semainavolisib | Phase 2 | Completed |
| NCT06492531 | Semainavolisib | Phase 2 | Recruiting |
| NCT07359607 | AGI-4446 | Phase 3 | Active |
| NCT04813897 | AGI-4446 | Phase 3 | Completed |
| NCT03074124 | AGI-4446 | Phase 3 | Terminated |
| NCT06250055 | Fixamavacamten | Phase 2 | Completed |
| NCT04349865 | Polalucimab | Phase 1/2 | Not yet recr... |
| NCT06446459 | IPN-3758 | Phase 1 | Not yet recr... |
| NCT04988959 | IPN-3758 | Phase 1 | Completed |